Albumin–Bilirubin Grade as a Predictor of Recurrence in Liver Cancer Treatment
Author Information
Author(s): Lee Chang Hun, You Ga Ram, Jo Hoon Gil, Jun Chung Hwan, Cho Eun Young, Kim In Hee, Choi Sung Kyu, Yoon Jae Hyun
Primary Institution: Jeonbuk National University
Hypothesis
The study investigates the role of the albumin–bilirubin (ALBI) grade as a predictor of tumor recurrence and overall survival in patients with hepatocellular carcinoma undergoing radiofrequency ablation.
Conclusion
The ALBI grade is an independent predictor of tumor recurrence and prognosis in patients with hepatocellular carcinoma following radiofrequency ablation.
Supporting Evidence
- The ALBI grade was the only significant predictor of overall survival.
- Age and Child–Pugh class B were also identified as independent predictors of tumor recurrence.
- Recurrence rates were high, with 52.3% of patients experiencing recurrence during follow-up.
Takeaway
This study found that a simple score called the ALBI grade can help doctors predict how likely it is for liver cancer to come back after treatment.
Methodology
The study reviewed medical records of treatment-naïve patients with hepatocellular carcinoma who underwent radiofrequency ablation at four hospitals in South Korea from 2008 to 2017.
Potential Biases
Potential biases due to the retrospective nature of the study and variations in RFA techniques across different hospitals.
Limitations
The study's retrospective design may introduce selection bias and limit control over confounding variables.
Participant Demographics
The mean age of participants was 66.3 years, with 75% male and most having liver cirrhosis.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website